Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells

被引：2

作者：

D'Arena, Giovanni ^{[1
]}

Ruggieri, Vitalba ^{[1
]}

D'Auria, Fiorella ^{[1
]}

La Rocca, Francesco ^{[1
]}

Simeon, Vittorio ^{[1
]}

Statuto, Teodora ^{[1
]}

Caivano, Antonella ^{[1
]}

Telesca, Donatella ^{[1
]}

Del Vecchio, Luigi ^{[2
]}

Musto, Pellegrino ^{[1
]}

机构：

[1] IRCCS Referral Canc Ctr Basilicata, Potenza, Italy

[2] Univ Naples Federico II, CEINGE Inst Adv Biotechnol, I-80138 Naples, Italy

来源：

LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 08期

关键词：

RITUXIMAB;

D O I：

10.3109/10428194.2014.999329

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2458 / 2459

页数：2

共 9 条

[1] Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia [J].

Badoux, Xavier C. ;

Keating, Michael J. ;

Wen, Sijin ;

Wierda, William G. ;

O'Brien, Susan M. ;

Faderl, Stefan ;

Sargent, Rachel ;

Burger, Jan A. ;

Ferrajoli, Alessandra .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) :584-591

[2]

D'Arena G, 2000, AM J HEMATOL, V64, P275

[3] Lenalidomide Induces Capping of CD20 and Cytoskeleton Proteins, to Enhance Rituximab Immune Recognition of Malignant B-Cells [J].

Gaidarova, Svetlana ;

Mendy, Derek ;

Heise, Carla ;

Aukerman, Sharon Lea ;

Daniel, Tom ;

Chopra, Rajesh ;

Lopez-Girona, Antonia .

BLOOD, 2010, 116 (21) :1173-1173

[4] Treating chronic lymphocytic leukemia with thalidomide and lenalidomide [J].

Giannopoulos, Krzysztof ;

Mertens, Daniel ;

Stilgenbauer, Stephan .

EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (18) :2857-2864

[5] How does lenalidomide target the chronic lymphocytic leukemia microenvironment? [J].

Kater, Arnon P. ;

Tonino, Sanne H. ;

Egle, Alexander ;

Ramsay, Alan G. .

BLOOD, 2014, 124 (14) :2184-2189

[6] Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells [J].

Lapalombella, Rosa ;

Yu, Bo ;

Triantafillou, Georgia ;

Liu, Qing ;

Butchar, Jonathan P. ;

Lozanski, Gerard ;

Ramanunni, Asha ;

Smith, Lisa L. ;

Blum, William ;

Andritsos, Leslie ;

Wang, Da-Sheng ;

Lehman, Amy ;

Chen, Ching-Shih ;

Johnson, Amy J. ;

Marcucci, Guido ;

Lee, Robert J. ;

Lee, L. James ;

Tridandapani, Susheela ;

Muthusamy, Natarajan ;

Byrd, John C. .

BLOOD, 2008, 112 (13) :5180-5189

[7] Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug [J].

Ramsay, Alan G. ;

Gribben, John G. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (09) :1198-1202

[8] Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo [J].

Reddy, Nishitha ;

Hernandez-Ilizaliturri, Francisco J. ;

Deeb, George ;

Roth, Mark ;

Vaughn, Mary ;

Knight, Joy ;

Wallace, Paul ;

Czuczman, Myron S. .

BRITISH JOURNAL OF HAEMATOLOGY, 2008, 140 (01) :36-45

[9] Rituximab: Mechanism of Action [J].

Weiner, George J. .

SEMINARS IN HEMATOLOGY, 2010, 47 (02) :115-123

← 1 →